Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genotype-guided Zeprumetostat Combination Therapy in Primary Refractory PTCL
NCT07493330Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Mar 2026
- Primary completion
- Dec 2029
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of zeprumetostat in peripheral T-cell lymphoma (PTCL) (4 arms), sponsored by Ruijin Hospital. Primary endpoints: Dose-Limiting Toxicity at 28 days and Overall Response Rate at 84 days. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
zeprumetostat
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT07493330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07493330.